Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at HC Wainwright

Celcuity (NASDAQ:CELC) had its target price reduced by equities research analysts at HC Wainwright from $155.00 to $150.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s target price indicates a potential upside of 124.58% from the stock’s previous close.

Several other equities research analysts have also weighed in on CELC. Stifel Nicolaus dropped their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. JPMorgan Chase & Co. initiated coverage on Celcuity in a report on Thursday, September 17th. They issued an “overweight” rating and a $157.00 price objective for the company. Zacks Research lowered Celcuity from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Craig Hallum restated a “buy” rating and set a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Finally, TD Cowen restated a “buy” rating and set a $145.00 target price on shares of Celcuity in a report on Wednesday, October 21st. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Celcuity has an average rating of “Moderate Buy” and a consensus price target of $151.79.

Celcuity Price Performance

CELC stock opened at $66.79 on Monday. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity has a 1 year low of $53.54 and a 1 year high of $151.02. The firm has a 50-day moving average of $75.11 and a 200 day moving average of $99.38. The company has a market cap of $3.27 billion, a P/E ratio of -14.18 and a beta of 0.16.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, beating the consensus estimate of ($1.51) by $0.30. On average, sell-side analysts forecast that Celcuity will post -4.98 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CELC. Hsbc Holdings PLC purchased a new stake in shares of Celcuity during the fourth quarter valued at approximately $1,058,000. California State Teachers Retirement System increased its position in shares of Celcuity by 91.2% during the first quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock valued at $2,920,000 after acquiring an additional 12,201 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Celcuity during the second quarter valued at approximately $153,928,000. E Fund Management Co. Ltd. purchased a new position in Celcuity in the 2nd quarter worth approximately $4,802,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Celcuity in the 2nd quarter worth approximately $2,927,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways.

Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

Founded in 2012 and headquartered in Minneapolis, Minnesota, Celcuity conducts clinical development in the United States and internationally.